Refine
Has Fulltext
- no (19)
Year of publication
Document Type
- Article (19) (remove)
Language
- English (19)
Is part of the Bibliography
- yes (19)
Keywords
- chronic kidney disease (3)
- endothelin-converting enzyme (3)
- neutral endopeptidase (3)
- Diabetic nephropathy (2)
- TGF-beta 1 (2)
- linagliptin (2)
- proteomic analysis (2)
- 2k1c renovascular hypertension (1)
- Angiotensin converting enzyme inhibitor (1)
- Chick embryos (1)
- D-galactosamine (1)
- DNA methylation (1)
- DPP-4 inhibition (1)
- DPP-4 inhibitor (1)
- DPP4 inhibition (1)
- Diabetic cardiomyopathy (1)
- Epigenetics (1)
- Fibrosis (1)
- Free vitamin D (1)
- Furosemide (1)
- Gestational diabetes (1)
- Gestational diabetes mellitus (1)
- Glp1r(-/-) mice (1)
- HNRNPA1 (1)
- Heart failure (1)
- High osmolarity (1)
- Inflammation (1)
- Lens (1)
- Linagliptin (1)
- Long term health (1)
- Loop diuretics (1)
- Metabolomics (1)
- Mortality (1)
- Pax6 (1)
- Phosphatidylcholine acyl-alkyl C 32:1 (1)
- Preeclampsia (1)
- Proline (1)
- Relaxin (1)
- Renal failure (1)
- Renin-angiotensin system (1)
- Retina (1)
- Single nucleotide polymorphism (1)
- Small for gestational age (1)
- Vitamin D binding protein (1)
- Vitamin D deficiency (1)
- YB-1 (1)
- acute liver failure (1)
- albuminuria (1)
- angiotensin receptor blockers (1)
- blood pressure (1)
- cardiac remodeling (1)
- children (1)
- collagen I (1)
- endothelin (1)
- fibrosis (1)
- foot and mouth disease (HFMD) (1)
- hand (1)
- low birth weight (LBW) (1)
- lower respiratory tract infections (LRTIs) (1)
- matrix metalloproteinases (1)
- oxidative stress (1)
- pneumonia (1)
- proteinuria (1)
- renovascular hypertension (1)
- thymosin beta 4 (1)
- vascular calcification (1)
- vascular smooth muscle cells (1)
Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect of the novel dipeptidyl peptidase-4 inhibitor linagliptin alone and in combination with the ARB telmisartan on the progression of diabetic nephropathy in diabetic endothelial nitric oxide synthase (eNOS) knockout mice. Methods: Sixty male eNOS knockout C57BL/6J mice were divided into four groups after receiving intraperitoneal high-dose streptozotocin: telmisartan (1 mg/kg), linagliptin (3 mg/kg), linagliptin + telmisartan (3 mg/kg + 1 mg/kg) and vehicle. Fourteen mice were used as non-diabetic controls. Results: After 12 weeks, urine and blood were obtained and blood pressure measured. Glucose concentrations were increased and similar in all diabetic groups. Telmisartan alone reduced systolic blood pressure by 5.9 mmHg versus diabetic controls (111.2 +/- 2.3 mmHg vs 117.1 +/- 2.2 mmHg; mean +/- SEM; P = 0.071). Combined treatment significantly reduced albuminuria compared with diabetic controls (71.7 +/- 15.3 mu g/24 h vs 170.8 +/- 34.2 mu g/24 h; P = 0.017), whereas the effects of single treatment with either telmisartan (97.8 +/- 26.4 mu g/24 h) or linagliptin (120.8 +/- 37.7 mu g/24 h) were not statistically significant. DPP-4 inhibition, alone and in combination, led to significantly lower plasma osteopontin levels compared with telmisartan alone. Histological analysis revealed reduced glomerulosclerosis after Linagliptin alone and in combination with telmisartan in comparison to non treated diabetic animals (p < 0.01 and p < 0.05). Kidney malonaldehyde immune-reactivity, a marker of oxidative stress, was significantly lower in animals treated with linagliptin. Conclusions: DPP-4 inhibition on top of ARB treatment significantly reduced urinary albumin excretion and oxidative stress in diabetic eNOS knockout mice. Linagliptin on top of an angiotensin II receptor blocker may offer a new therapeutic approach for patients with diabetic nephropathy.